Examples of 'cetuximab' in a sentence
Meaning of "cetuximab"
cetuximab (noun): Cetuximab is a monoclonal antibody medication used in the treatment of certain types of cancer. It works by targeting specific proteins in cancer cells to inhibit their growth and spread. Cetuximab is commonly used to treat colorectal cancer and head and neck cancer. It is typically administered intravenously under medical supervision
Show more definitions
- A chimeric (mouse/human) monoclonal antibody that targets epidermal growth factor receptor.
How to use "cetuximab" in a sentence
Basic
Advanced
cetuximab
Cetuximab is also used in the treatment of throat cancer.
These include cetuximab and panitumumab.
Cetuximab and panitumumab are examples of monoclonal antibody inhibitors.
Examples include cetuximab and panitumumab.
Cetuximab was comparable to the bivalent parental control antibodies.
Erlotinib and cetuximab were used as controls.
Cetuximab alleviates neuropathic pain despite tumour progression.
There are no data on the effect of cetuximab on human fertility.
Do not combine cetuximab or panitumumab to chemotherapy containing capecitabine.
Hypomagnesaemia is reversible following discontinuation of cetuximab.
Cetuximab in combination with chemotherapy.
Randomisation was stratified by prior cetuximab treatment.
See cetuximab prescribing information.
The active substance is cetuximab.
This is not the case if cetuximab is administered in mono therapy.
See also
Subjects in the control arm received treatment with cetuximab.
Cetuximab as a single agent.
Patients receive cetuximab as in ar.
Cetuximab in combination with radiation therapy for locally advanced disease.
First clinical activity data of the combination of monalizumab and cetuximab.
Cetuximab is a targeted therapy.
No conclusive data on the neutralising effect of HACAs on cetuximab is available to date.
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
No other formal interaction studies with cetuximab have been performed in humans.
Cetuximab is administered intravenously.
Treatment of recurrent squamous cell carcinoma of the skin with cetuximab.
Cetuximab also stimulates.
One example of a large molecule according to the present invention is cetuximab.
The safety and effectiveness of cetuximab in paediatric patients have not been established.
Cetuximab stops the growth factors from attaching to receptors on the cancer.
There is no relevant use of cetuximab in the paediatric population in the granted indications.
Cetuximab was held.
Individual cases of interstitial lung disorders of unknown causal relationship to cetuximab have been reported.
It is recommended that cetuximab treatment be continued until progression of the underlying disease.
Determination of serum electrolyte levels is recommended prior to and periodically during cetuximab treatment.
Cetuximab serum concentrations reached stable levels after three weeks of cetuximab monotherapy.
Laboratory and clinical studies on the utility of cetuximab in this context are conflicting.
Cetuximab may be administered with a higher initial dose followed by lower subsequent doses.
Objective response rate and progression free survival time were significantly improved with cetuximab.
Cetuximab acts through blocking oncogenic signaling and by ADCC.
Be sure to tell your doctor how you are feeling during your treatment with cetuximab.
The TLD may not comprise cetuximab or fragment thereof.
This effect was observed in a patient treated with Cetuximab.
Cetuximab does not bind to other receptors belonging to the HER family.
Innate pharma announces phase ii results from monalizumab and cetuximab combination in head and neck.
Notable among these is Cetuximab that is used in advanced cases of mouth cancer.
The third experimental arm used an intermittent OxMdG or XELOX regimen without cetuximab.
The combination of cetuximab and concurrent chemoradiotherapy is currently being investigated in phase III trials.
The effects of the combination of radiation with Chem and Cetuximab are also studied.
Cetuximab is a monoclonal antibody targeted against EGFR.
